Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Investment
    • Japanese regulator...

    Japanese regulator PMDA completes inspection of Lupin Mandideep facility unit, no major observations

    Medical Dialogues BureauWritten by Medical Dialogues Bureau Published On 2019-06-06T14:05:40+05:30  |  Updated On 6 Jun 2019 8:35 AM GMT
    Japanese regulator PMDA completes inspection of Lupin Mandideep facility unit, no major observations

    New Delhi: Drug firm Lupin Tuesday said Japanese regulatory agency, PMDA, has concluded the inspection of Unit 2 at Mandideep facility in Madhya Pradesh with no major observations.


    The inspection was conducted between May 14 and May 17, 2019, Lupin said in a statement.


    The good manufacturing practices (GMP) inspection by the Pharmaceutical and Medical Devices Agency (PMDA), Japan of the company's Mandideep facility (Unit-2) has been completed, it said.


    Read Also: Lupin’s Goa facility may face regulatory action, says USFDA


    "The PMDA inspection closed with no critical or major observations," Lupin said.


    PMDA is Japanese regulatory agency that protects public health by assuring the safety, efficacy and quality of pharmaceuticals and medical devices.


    Shares of Lupin Tuesday closed at Rs 742.20 per scrip on the BSE, down 0.39 per cent from its previous close.


    BSE Drug firm Lupin efficacy GMP inspection good manufacturing practices Lupin Lupins Mandideep facility Mandideep facility madhya pradesh Medical Devices Agency pharmaceutical PMDA PMDA inspection PMDA japan Quality safety Shares of Lupin 
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier

      This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:

      Search only trustworthy HONcode health websites:

      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2020 Minerva Medical Treatment Pvt Ltd

      © 2020 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      X